<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05792813</url>
  </required_header>
  <id_info>
    <org_study_id>Xiyuannanke</org_study_id>
    <nct_id>NCT05792813</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Linggui Yangyuan Paste in Patients With Male Infertility</brief_title>
  <official_title>Xiyuan Hospital of China Academy of Chinese Medical Sciences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiyuan Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Fifth People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Traditional Chinese Medicine Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiyuan Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Male infertility affects millions of males worldwide and is rising in prevalence due to&#xD;
      social and environmental conditions. Asthenozoospermia (AZS) and oligoasthenozoospermia (OA)&#xD;
      are the major causes of male infertility. The diagnosis of male infertility has a negative&#xD;
      effect on men's physical and psychological status, poses a threat to their social&#xD;
      relationships, lowers self-esteem, and disrupts family harmony. At present, the treatment of&#xD;
      ASZ and OA are all mostly empirical, including antioxidants, endocrine therapy, and&#xD;
      anti-infection. However, there are still limitations due to inefficiencies. Linggui Yangyuan&#xD;
      paste (LGYY), a traditional Chinese compound herbal past, had been used to treat ASZ and OA&#xD;
      for several years at the Xiyuan Hospital of China Academy of Chinese Medical Sciences. The&#xD;
      investigators designed this program to study the efficacy and safety of LGYY for the&#xD;
      treatment of patients with male infertility (AZS and OA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2023</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total progressive motile sperm count (TPMSC) from baseline to post-treatment</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>TPMSC change from baseline to post-treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The total sperm count change from baseline to post-treatment</measure>
    <time_frame>Baseline, 4, 8, 12 weeks</time_frame>
    <description>the total sperm count change from baseline to post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>semen volume change from baseline to post-treatment</measure>
    <time_frame>Baseline, 4, 8, 12 weeks</time_frame>
    <description>1) semen volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sperm density change from baseline to post-treatment</measure>
    <time_frame>Baseline, 4, 8, 12 weeks</time_frame>
    <description>2) sperm density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR rate change from baseline to post-treatment</measure>
    <time_frame>Baseline, 4, 8, 12 weeks</time_frame>
    <description>3) Semen parameter PR rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR+NP rate change from baseline to post-treatment</measure>
    <time_frame>Baseline, 4, 8, 12 weeks</time_frame>
    <description>4) PR+NP rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chinese Medicine Symptoms Score (CMSS) change from baseline to post-treatment</measure>
    <time_frame>Baseline, 4, 8, 12 weeks of treatment and 12 weeks of follow-up (24 week)</time_frame>
    <description>Scores range from 0 to 33 with higher scores indicating greater burden of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>spouse pregnancy rate</measure>
    <time_frame>Baseline, 12 weeks of treatment and 12 weeks of follow-up (24 week)</time_frame>
    <description>difference in the number of pregnancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to pregnancy</measure>
    <time_frame>Baseline, 12 weeks of treatment and 12 weeks of follow-up (24 week)</time_frame>
    <description>The time required for pregnancy in this study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Male Infertility</condition>
  <condition>Asthenozoospermia</condition>
  <condition>Oligoasthenozoospermia</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LGYY+ WZYZ mimetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>WZYZ + LGYY mimetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGYY</intervention_name>
    <description>LGYY = Linggui Yangyuan paste</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGYY mimetic</intervention_name>
    <description>LGYY = Linggui Yangyuan paste</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WZYZ</intervention_name>
    <description>WZYZ= Wuzi Yanzong oral solution</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WZYZ mimetic</intervention_name>
    <description>WZYZ= Wuzi Yanzong oral solution</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participants must meet all following criteria at the time of randomization to be&#xD;
             eligible for recruitment :&#xD;
&#xD;
               1. Study participants met the diagnostic criteria for male infertility 1)inability&#xD;
                  to have a child after at least 1 year of marriage with regular sexual life and&#xD;
                  without using any preventive methods 2)normal fertile female partner&#xD;
&#xD;
               2. Study participants met the diagnostic criteria for AZS or OA&#xD;
&#xD;
        For AZS:&#xD;
&#xD;
          1. sperm concentration ≥15 × 106/ mL&#xD;
&#xD;
          2. PR &lt;32%&#xD;
&#xD;
        For OA:&#xD;
&#xD;
          1. sperm concentration &lt;15 × 106/ mL&#xD;
&#xD;
          2. PR &lt;32% (3) Study participants met the TCM diagnosis criteria for kidney deficiency&#xD;
             and blood stasis (4) Men aged 22 to 45 years (5) The participants signed informed&#xD;
             consent forms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The trial exclusion criteria included any of the following:&#xD;
&#xD;
               1. infertility is caused by the inability to complete sexual intercourse, including&#xD;
                  but not limited to erectile dysfunction or ejaculatory disorders&#xD;
&#xD;
               2. with infertility caused by organic lesions of the reproductive system&#xD;
&#xD;
               3. with reproductive system infection, such as chlamydia trachomatis or mycoplasma&#xD;
                  infection&#xD;
&#xD;
               4. with palpable varicocele&#xD;
&#xD;
               5. with abnormal and clinical significance of sex hormone (FSH, LH, T)&#xD;
&#xD;
               6. complicated with liver and kidney dysfunction, severe basic diseases such as&#xD;
                  diabetes, cardiovascular and cerebrovascular diseases, mental diseases, malignant&#xD;
                  tumors, or serious organic diseases&#xD;
&#xD;
               7. with a history of allergy to any medicine or ingredients used in this study&#xD;
&#xD;
               8. receive other relevant treatment for the disease 2 weeks before treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>shengjing liu, Phd.</last_name>
    <phone>+86 01062835134</phone>
    <email>liu-shengjing@qq.com</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 8, 2023</study_first_submitted>
  <study_first_submitted_qc>March 30, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>April 24, 2023</last_update_submitted>
  <last_update_submitted_qc>April 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
    <mesh_term>Asthenozoospermia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

